Improved Cash Generation & Net CashSustained positive operating cash flow and restored free cash flow with a net cash balance materially improves liquidity and reduces refinancing risk. Durable cash generation funds targeted capex, supports the restructuring envelope and provides flexibility through API demand cycles over the next 2–3 years.

Conservative Balance Sheet / Low LeverageVery low leverage gives the company financial flexibility to absorb restructuring costs and invest selectively in strategic projects without pressuring liquidity. This balance-sheet cushion supports multi-year transition to higher-margin differentiated APIs and shields against cyclical pharma demand shocks.

Shift To Differentiated Products & Stronger CDMO MixA growing share of differentiated APIs and a later-stage CDMO project mix improve revenue defensibility and reduce exposure to commodity price pressure. Progress toward a 70% differentiated sales target is a structural move to steadier margins and more durable, contract-backed revenue streams over coming years.

Bears Say

Declining Revenue And Widened Net LossesSustained top-line deterioration coupled with material net losses erodes earnings power and shareholder equity. Continued revenue weakness undermines operating leverage, raises per-unit costs, increases probability of further impairments and constrains the company's ability to invest for growth over the medium term.

Significant Impairments & Non‑recurring ChargesLarge impairments and one-off charges reflect prior overinvestment or value destruction in certain projects and reduce book equity. These items signal risks of further write‑downs, weaken capital cushions and may limit strategic flexibility while management executes the transformation over the next 2–3 years.

Material 2026 Top-line Headwind & Customer Concentration LossDeliberate SKU discontinuations and a sharp drop in a major customer create a structural revenue gap. A guided ~10% sales decline reduces scale benefits, pressures margins and delays FOCUS‑27 targets, increasing execution risk and extending the timeline to restore prior growth and profitability.

Euroapi SA News

Euroapi SA Earnings Call: Discipline Amid Declining Sales

Euroapi SA (($FR:EAPI)) has held its Q4 earnings call. Read on for the main highlights of the call....

15d ago

EAPI

EAPI FAQ

What was Euroapi SA’s price range in the past 12 months?

Euroapi SA lowest stock price was €1.25 and its highest was €3.57 in the past 12 months.

What is Euroapi SA’s market cap?

Euroapi SA’s market cap is €124.38M.

When is Euroapi SA’s upcoming earnings report date?

Euroapi SA’s upcoming earnings report date is Jul 28, 2026 which is in 127 days.

How were Euroapi SA’s earnings last quarter?

Euroapi SA released its earnings results on Mar 03, 2026. The company reported -€1.929 earnings per share for the quarter, missing the consensus estimate of N/A by -€1.929.

Is Euroapi SA overvalued?

According to Wall Street analysts Euroapi SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Euroapi SA pay dividends?

Euroapi SA does not currently pay dividends.

What is Euroapi SA’s EPS estimate?

Euroapi SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Euroapi SA have?

Euroapi SA has 95,589,775 shares outstanding.

What happened to Euroapi SA’s price movement after its last earnings report?

Euroapi SA reported an EPS of -€1.929 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.513%.

Which hedge fund is a major shareholder of Euroapi SA?

Currently, no hedge funds are holding shares in FR:EAPI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Euroapi SA

Euroapi SA (EAPI) is a leading European contract development and manufacturing organization (CDMO) specializing in the production of active pharmaceutical ingredients (APIs) for the pharmaceutical industry. The company focuses on providing high-quality, customized solutions for its clients across various therapeutic areas, including oncology, cardiovascular, and infectious diseases. Euroapi operates several state-of-the-art manufacturing facilities and is committed to sustainability and innovation in the production of APIs.